Karyopharm Therapeutics Inc (KPTI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $394,660
Last updated: Nov 10, 2026 at 7:59 PM ET
Karyopharm Therapeutics Inc (KPTI) Stock Chart
Karyopharm Therapeutics (KPTI) has a latest price of $0.02 on Nov 10, 2026, 99.8% below its 52-week high of $10.99. Its price fell 88.6% over the 12 months through Oct 2026. The month-end price fell 99.4% over the 10 years through Oct 2026, a compound annual decline of 39.9%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $330.58 in Apr 2020 and its lowest $0.66 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart KPTI with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for KPTI.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 99.1%, and over 6 months it fell 99.8%. The month-end price fell 94.9% over the 3 years through Oct 2026, a compound annual decline of 63.0%.
| Period | Change |
|---|---|
| 1 month | -96.6% |
| 3 months | -99.1% |
| 6 months | -99.8% |
| Period | Change | Per year |
|---|---|---|
| 1 year | -88.6% | -88.6% |
| 3 years | -94.9% | -63.0% |
| 5 years | -99.2% | -61.8% |
| 10 years | -99.4% | -39.9% |
Price by Year
Its best calendar year was 2019, when the price rose 104.6%, and its weakest was 2023, when it fell 74.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.66 | -91.0% |
| 2025 | $7.36 | -27.4% |
| 2024 | $10.14 | -21.8% |
| 2023 | $12.97 | -74.6% |
| 2022 | $50.97 | -47.1% |
| 2021 | $96.40 | -58.5% |
| 2020 | $232.08 | -19.2% |
| 2019 | $287.41 | +104.6% |
| 2018 | $140.48 | -2.4% |
| 2017 | $143.93 | +2.1% |
Trading Range
The price is 98.2% below its 50-day average of $0.96 and 99.7% below its 200-day average of $5.81.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 10, 2026) | $0.02 | |
| 52-week high | $10.99 | -99.8% |
| 52-week low | $0.02 | +2.4% |
| 50-day average | $0.96 | -98.2% |
| 200-day average | $5.81 | -99.7% |
Price Risk
Over 3 years, its largest fall from a peak was 99.9%.
| Measure | Value |
|---|---|
| 1-year beta | 1.07 |
| Largest fall, 1 year | -99.8% |
| Largest fall, 3 years | -99.9% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About KPTI
What is KPTI's 1-year price change?
Karyopharm Therapeutics's price fell 88.6% over the 12 months through Oct 2026.
What is KPTI's 5-year price change?
Karyopharm Therapeutics's month-end price fell 99.2% over the 5 years through Oct 2026, a compound annual decline of 61.8%. These figures leave out dividends.
What is KPTI's 52-week high and low?
Karyopharm Therapeutics's 52-week high is $10.99 and its 52-week low is $0.02. Its latest price of $0.02 on Nov 10, 2026 is 99.8% below the high.
What is KPTI's beta?
Karyopharm Therapeutics's 1-year beta against the S&P 500 is 1.07, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 99.8%.
Is the KPTI chart free?
Yes. Advanced Charting for KPTI is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
KPTI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors